CureVac NV has appointed Mehdi Shahidi, an oncologist and drug development executive, to its supervisory board amid the company’s plans to lay the clinical foundations for a new generation of mRNA-based cancer vaccines. Dr Shahidi is currently chief executive officer of Petalion Therapeutics, a UK-based biotech developing targeted dendrimer therapies in oncology as well as a venture partner at Medicxi, a life sciences investment firm. He was previously global head of medicine and chief medical officer at Boehringer Ingelheim International where he oversaw five drug approvals. His appointment took effect at CureVac SE at the beginning of September, while his appointment to CureVac NV will be considered at the annual general meeting in June 2025.
CureVac announced the appointment on 15 August 2024.
Copyright 2024 Evernow Publishing Ltd.